Clinical approval of three kinds of corticosteroids in Xianju pharmaceutical
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the website of the State Food and Drug Administration (CFDA) on May 29, the status of the 3.1-class chemical difacote and difacote tablets applied for clinical application of Xianju pharmaceutical was changed to "certificate preparation completed - approved document" The company responded on the investor interaction platform that it has obtained the product clinical approval document and can carry out clinical trials Difacote belongs to the third generation of glucocorticoids, which has anti-inflammatory and anti allergic effects It is used for adrenocortical hypofunction, rheumatism, dermatosis, tuberculosis, hematopoiesis system diseases, etc Xianju pharmaceutical applied for clinical approval of the drug in March 2011 At present, there is no domestic enterprise to produce the product, and the original research drug has not entered the market of our country CFDA shows that except for Xianju pharmaceutical, only TIANYAO company has declared the product The latter declared clinical application as early as November 2006, and obtained clinical approval in August 2008 So far, it has not declared production Xianju pharmaceutical is mainly engaged in the pharmaceutical industry, mainly including corticosteroids, gynecological and family planning drugs, anesthesia and muscle relaxant drugs Among them, corticosteroids products are the largest source of revenue of the company, and the operating revenue accounts for 40% of the total revenue.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
